SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Comparative pharmacokinetics of levodopa-carbidopa intestinal gel infusion and foslevodopa-foscarbidopa continuous subcutaneous infusion therapies in advanced Parkinson's disease.

Parkinsonism Relat Disord · 2026-01-20

DOI: 10.1016/j.parkreldis.2026.108197PMID: 41570355

Check source for accessComparative Study; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

IntroductionLevodopa-carbidopa intestinal gel therapy (LCIG) and foslevodopa-foscarbidopa continuous subcutaneous infusion therapy (FOCS) are device-aided therapies for advanced Parkinson's disease. Comparative real-world pharmacokinetic (PK) data remain limited. This study aimed to compare overall plasma levodopa exposure between LCIG and FOCS.MethodsPatients who initiated LCIG or FOCS, completed dose optimization, and underwent a standardized levodopa challenge were evaluated. Plasma levodopa concentrations and motor states were assessed repeatedly over 420 min. Overall concentrations were compared using a linear mixed-effects model. Steady-state concentration (SSConc; 300-420 min) and its relationship with body-surface-area-adjusted infusion rate were examined. Time to On and the plasma concentration at On transition (On-Conc) were analyzed.ResultsMean plasma levodopa concentrations tended to be higher with FOCS, although the group effect was not significant (geometric mean ratio: 1.38; p = 0.060). SSConc was higher with FOCS (12.85 ± 2.78 vs. 9.23 ± 1.61 nmol/mL). Both therapies showed linear SSConc-dose relationships, with a steeper slope for FOCS. LCIG produced a faster transition to the On state (median 45 vs. 150 min), whereas On-Conc was similar between groups (approximately 10 nmol/mL). In the FOCS group, baseline Off occurred only when nighttime infusion rates were ≤74 % of daytime rates.ConclusionLCIG and FOCS show distinct PK profiles despite similar overall concentrations. LCIG provides a rapid rise in levodopa levels and earlier On onset, whereas FOCS yields higher SSConc values and greater dose-concentration efficiency, informing titration approaches, nighttime infusion settings, and individualized selection of continuous infusion-based dopaminergic therapy.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.